GlassScriptPhysician profile
Karen E Thrift
NPI 1093031619
$8,589.39
in general payments reported to CMS, 2019-2025
44 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,210 · 2022: $1,275 · 2023: $896 · 2024: $3,209 · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,867 · Travel and Lodging: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,866.53 |
| Travel and Lodging | $1,238.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,013.36 | 2021-2025 | Minimed 780g, Interstim |
| Novo Nordisk INC | $858.78 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $799.97 | 2021-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $780.09 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $750.20 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $438.07 | 2021-2025 | |
| Pfizer INC. | $272.58 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.17 | 2023-2025 | Jardiance |
| Abbvie INC. | $262.94 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.23 | 2021-2025 | |
| Abiomed | $176.02 | 2024 | Impella |
| Phathom Pharmaceuticals, INC. | $171.56 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $162.17 | 2021-2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $140.41 | 2021 | |
| Janssen Biotech, INC. | $124.94 | 2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.82 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $103.38 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $80.53 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Otsuka America Pharmaceutical, INC. | $63.15 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $59.53 | 2022 | |
| Sequel Med Tech, LLC | $58.68 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $54.21 | 2023-2024 | Xarelto |
| Boston Scientific Corporation | $52.92 | 2023 | Watchman Access System, Watchman |
| Averitas Pharma INC. | $52.14 | 2025 | Qutenza |
| Abbott Laboratories | $45.69 | 2021-2025 | Freestyle Libre 3 |
| Coloplast Corp | $45.00 | 2024 | |
| Insulet Corporation | $42.98 | 2023-2024 | Omnipod |
| Dexcom, INC. | $39.45 | 2021-2023 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $39.17 | 2025 | Yorvipath |
| Viiv Healthcare Company | $35.42 | 2025 | Dovato |
| Nestle Healthcare Nutrition INC. | $34.06 | 2021-2023 | |
| Rhythm Pharmaceuticals, INC. | $29.61 | 2025 | Imcivree |
| Shield Therapeutics INC | $28.72 | 2023-2024 | |
| Glaxosmithkline, LLC. | $28.34 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $21.34 | 2022 | |
| Antares Pharma, INC. | $21.14 | 2025 | Xyosted |
| Beta Bionics, INC. | $19.51 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.65 | 2025 | Caplyta |
| Cequr Corporation | $18.36 | 2024 | Cequr Simplicity |
| Corcept Therapeutics | $17.57 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $16.19 | 2024 | Capvaxive |
| Exact Sciences Corporation | $16.11 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $15.22 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Thrift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.